Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Mitomycin C + Oncovin + semustine + thiotepa** is a combination chemotherapy regimen consisting of four cytotoxic agents: mitomycin C (an antibiotic that inhibits DNA synthesis by cross-linking DNA strands), Oncovin (vincristine, a vinca alkaloid that disrupts microtubule formation and mitosis), semustine (a nitrosourea alkylating agent that methylates DNA causing strand breaks), and thiotepa (an alkylating agent that cross-links DNA to prevent replication). This multi-agent approach leverages complementary mechanisms to enhance antitumor efficacy against rapidly dividing cancer cells, primarily used historically in gastrointestinal cancers such as colorectal or gastric tumors, though specific trial data for this exact quartet is limited.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mitomycin C + Oncovin + semustine + thiotepa.